Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply

Affiliations

¹ Hematology Division, Massachusetts General Hospital, Boston, MA 02139, USA. Electronic address: hal-samkari@mgh.harvard.edu.
² Division of Hematology and Medical Oncology and Division of Pediatric Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
³ Department of Hematology, Saitama Medical University Hospital, Saitama, Japan.
⁴ Lombardi Cancer Center, Division of Hematology, Georgetown University, Washington, DC, USA.

Comment

Hanny Al-Samkari et al. Lancet. 2024.

. 2024 Aug 3;404(10451):434.

doi: 10.1016/S0140-6736(24)01263-7.

¹ Hematology Division, Massachusetts General Hospital, Boston, MA 02139, USA. Electronic address: hal-samkari@mgh.harvard.edu.
² Division of Hematology and Medical Oncology and Division of Pediatric Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
³ Department of Hematology, Saitama Medical University Hospital, Saitama, Japan.
⁴ Lombardi Cancer Center, Division of Hematology, Georgetown University, Washington, DC, USA.

No abstract available

Comment on

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.